These findings highlight the potential of adiponectin as an early biomarker of metabolic dysfunction and cardiometabolic risk in LBW individuals, offering a valuable tool in clinical practice for the prevention of T2D. This evidence concerns the gene ADIPOQ and type 2 diabetes mellitus.